Quick Answer
CATALYST PHARMACEUTICALS, INC. reported Total Revenue of $588.99 million for fiscal year 2025.
CATALYST PHARMACEUTICALS, INC. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | $588.99M +19.8% |
$491.73M +23.5% |
$398.20M +85.9% |
$214.20M +52.1% |
$140.83M +18.3% |
$119.07M +16.4% |
| Revenue (ASC 606) | $588.99M +19.8% |
$491.73M +23.5% |
$398.20M +85.9% |
$214.20M +52.1% |
$140.83M +18.3% |
$119.07M +16.4% |
| Net Income | $214.33M +30.8% |
$163.89M +129.5% |
$71.41M -14.0% |
$83.08M +110.4% |
$39.48M -47.3% |
$74.98M +135.2% |
| Diluted EPS | $1.68 +28.2% |
$1.31 +107.9% |
$0.63 -16.0% |
$0.75 +102.7% |
$0.37 -47.9% |
$0.71 +136.7% |
| Total Assets | $1.10B +29.7% |
$851.41M +81.1% |
$470.11M +25.2% |
$375.63M +58.0% |
$237.79M +23.6% |
$192.35M +71.2% |
| Cash and Equivalents | $709.17M +37.0% |
$517.55M +276.0% |
$137.64M -53.9% |
$298.39M +74.0% |
$171.44M +31.6% |
$130.24M +45.5% |
| Stockholders Equity | $954.27M +31.1% |
$727.63M +87.6% |
$387.88M +29.1% |
$300.42M +45.2% |
$206.83M +22.0% |
$169.60M +93.5% |
| R&D Expense | $12.71M +0.5% |
$12.65M -86.4% |
$93.15M +370.7% |
$19.79M +16.8% |
$16.94M +2.7% |
$16.50M -12.5% |
| Operating Income | $257.78M +32.1% |
$195.12M +124.8% |
$86.81M -14.8% |
$101.84M +94.4% |
$52.38M +26.8% |
$41.30M +29.8% |
| Shares Outstanding | 122.51M +1.4% |
120.88M +12.8% |
107.12M +1.8% |
105.26M +2.2% |
102.99M -0.8% |
103.78M +0.4% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2025 | $148.39M | +15.3% | +1.2% |
| Revenue (ASC 606) | September 30, 2025 | $148.39M | +15.3% | +1.2% |
| Net Income | September 30, 2025 | $52.78M | +20.3% | +1.3% |
| Diluted EPS | September 30, 2025 | $0.42 | +20.0% | +2.4% |
| Total Assets | September 30, 2025 | $1.05B | +36.2% | +8.2% |
| Cash and Equivalents | September 30, 2025 | $689.89M | +56.0% | +5.7% |
| Stockholders Equity | September 30, 2025 | $920.25M | +39.2% | +7.5% |
| R&D Expense | September 30, 2025 | $2.66M | -19.1% | -39.0% |
| Operating Income | September 30, 2025 | $66.27M | +30.2% | -0.0% |
| Shares Outstanding | September 30, 2025 | 123.26M | +3.4% | +0.7% |
- CATALYST PHARMACEUTICALS, INC. reported Total Revenue of $588.99 million for fiscal year 2025.
- CATALYST PHARMACEUTICALS, INC. showed an increase of +19.8% in Total Revenue compared to the prior fiscal year.
- CATALYST PHARMACEUTICALS, INC. reported Revenue (ASC 606) of $588.99 million for fiscal year 2025.
- CATALYST PHARMACEUTICALS, INC. showed an increase of +19.8% in Revenue (ASC 606) compared to the prior fiscal year.
- CATALYST PHARMACEUTICALS, INC. reported Net Income of $214.33 million for fiscal year 2025.
- CATALYST PHARMACEUTICALS, INC. showed an increase of +30.8% in Net Income compared to the prior fiscal year.
- CATALYST PHARMACEUTICALS, INC. reported Diluted EPS of $1.68 per share for fiscal year 2025.
- CATALYST PHARMACEUTICALS, INC. showed an increase of +28.2% in Diluted EPS compared to the prior fiscal year.
- CATALYST PHARMACEUTICALS, INC. reported Total Assets of $1.10 billion for fiscal year 2025.
- CATALYST PHARMACEUTICALS, INC. showed an increase of +29.7% in Total Assets compared to the prior fiscal year.
- CATALYST PHARMACEUTICALS, INC. reported Cash and Equivalents of $709.17 million for fiscal year 2025.
- CATALYST PHARMACEUTICALS, INC. showed an increase of +37.0% in Cash and Equivalents compared to the prior fiscal year.
- CATALYST PHARMACEUTICALS, INC. reported Stockholders Equity of $954.27 million for fiscal year 2025.
- CATALYST PHARMACEUTICALS, INC. showed an increase of +31.1% in Stockholders Equity compared to the prior fiscal year.
- CATALYST PHARMACEUTICALS, INC. reported R&D Expense of $12.71 million for fiscal year 2025.
- CATALYST PHARMACEUTICALS, INC. showed an increase of +0.5% in R&D Expense compared to the prior fiscal year.
- CATALYST PHARMACEUTICALS, INC. reported Operating Income of $257.78 million for fiscal year 2025.
- CATALYST PHARMACEUTICALS, INC. showed an increase of +32.1% in Operating Income compared to the prior fiscal year.
- CATALYST PHARMACEUTICALS, INC. reported Shares Outstanding of 122.51 million shares for fiscal year 2025.
- CATALYST PHARMACEUTICALS, INC. showed an increase of +1.4% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: